



NAILFOLD CAPILLAROSCOPIC CHANGES IN EGYPTIAN PATIENTS WITH PSORIATIC ARTHRITIS IN COMPARISON TO RHEUMATOID ARTHRITIS

Thesis

Submitted for Partial Fulfillment of master Degree
In Internal Medicine and Rheumatology

By

Nouran Mohammed Elshahat
(M.B.,B.Ch.)

Supervised by

Prof. Dr. Adel Mahmoud Ali ELSayed

Professor of Internal Medicine and Head of Rheumatology
Department
Faculty of Medicine - Ain Shams University

Dr. Sherin Mohamed Hosny

Assistant Professor of Internal Medicine and Rheumatology
Faculty of Medicine - Ain shams University

Dr. Fatma Mohammad Aboud

Lecturer of Internal Medicine and Rheumatology
Faculty of Medicine - Ain shams University

Faculty of Medicine
Ain Shams University
2019



List of Contents

Title	Page
▪ List of Abbreviations	I
▪ List of Tables	VI
▪ List of Figures	IX
▪ Introduction	1
▪ Aim of the Work	3
▪ Review of Literature	
- Chapter (1): Rheumatoid Arthritis	4
- Chapter (2): Psoriatic Arthritis.....	39
- Chapter (3): Nailfold capillaroscopy	71
▪ Patients and Methods	84
▪ Results	93
▪ Discussion	125
▪ Summary and Conclusion	135
▪ Recommendations	139
▪ References	140
▪ Arabic Summary	--

List of Abbreviations

Abs	Antibodies
ACPA	Anti-cyclic citrullinated peptide Antibodies
ACR	American College of Rheumatology
ALT	Alanine Aminotransferase
Anti-MCV	Antibodies against mutated citrullinated Vimentin
APC	Antigen presenting cells
ASQOL	Ankylosing Spondylitis Quality of Life Questionnaire
AST	Aspartate Aminotransferase
BASDAI	Bath Ankylosing Spondylitis Disease Activity Index
BCR	B cell receptor
bDMARDS	Biologic disease modifying anti- rheumatic drugs
BHPR	British Health Professionals in Rheumatology
BSR	British society of Rheumatology
cAMP	cyclic adenosine monophosphate
CASPAR	classification criteria for psoriatic arthritis
CBC	Complete blood count
CCP	Cyclic citrullinated peptide
CCR6	Chemokine receptor 6
CDAI	Clinical Disease Activity Index
cDMARDS	Conventional disease modifying anti- rheumatic drugs
CL	Capillary length

List of Abbreviations

COX	Cyclo-oxygenase
CPDAI	Composite Psoriatic Disease Activity Index
CPK	Creatine phosphokinase
CRP	C-reactive protein
CS	Cigarette smoking
CT	Computerized tomography
CTLA	Cytotoxic T-lymphocyte associated antigen
CTS	Carpal tunnel syndrome
CW	Capillary width
DAPSA	Disease Activity Index for Psoriatic Arthritis
DAS	Disease activity score
DAS28	DAS based on 28 joint counts
DD	Disease duration
DIP	Distal interphalangeal
DLQI	Dermatology Quality of Life Index
DM	Dermatomyositis
DMARDS	Disease modifying anti-rheumatic drugs
ESR	Erythrocyte sedimentation rate
EULAR	European League against Rheumatism
FDA	Food and Drug administration
GCS	Glucocorticosteroids
G-CSF	Granulocyte-colony stimulating factor
GH	General health
GIT	Gastrointestinal tract

List of Abbreviations

GN	Glomerulonephritis
GRAPPA	Group for research and assessment of Psoriasis and Psoriatic Arthritis
GWAS	Genome-wide association studies
HAQ	Health Assessment Questionnaire
Hb	Hemoglobin
HCQ	Hydroxychloroquine
HLA	Human Leucocyte Antigen
HLADRB	Human Leucocyte Antigen Determinant Region
HRQoL	Health-related quality of life
HS	Highly significant
IBD	Inflammatory bowel disease
IFCC	The International Federation of Clinical Chemistry
Ig	Immunoglobulin
IGU	Iguratimod
IL	Inter-leukin
ILD	Interstitial lung disease
IPF	Interstitial pulmonary fibrosis
IQR	Inter-quartile range
JAK	Janus kinase
MCP	Metacarpophalangeal
MCTD	Mixed connective tissue disease
MHC	Major histocompatibility complex
MHZ	Mega hertz
MMPS	Matrix metalloproteinases
MRI	Magnetic resonance imaging

List of Abbreviations

MR-pred	Modified-release prednisone
MTP	Metatarsophalangeal
MTX	Methotrexate
NFC	Nailfold capillaroscopy
NF-Kb	Nuclear factor of κ B
NS	Non significant
NSAIDS	Non-steroidal anti-inflammatory drugs
OMERACT	Outcome Measures in Rheumatoid Arthritis Clinical Trials
PADI4	Peptidylarginine-deiminase 4
PASI	Psoriasis Area and Severity Index
PDE4	Phosphodiesterase
PGE2	Prostaglandin E2
PIP	Proximal interphalangeal
PLT	Platelets
PP	Patient pain
PsA	Psoriatic arthritis
PtGA	Patient global assessment
RA	Rheumatoid arthritis
RABBIT	German acronym for Rheumatoid Arthritis-Observation of Biologic Therapy
RANκL	Receptor activator of nuclear factor κ B ligand
RF	Rheumatoid factor
ROM	Range of motion
RP	Raynaud's phenomenon
RTX	Rituximab
S	Significant

List of Abbreviations

SD	Standard deviation
SDAI	Simplified Disease Activity Index
SJC	Swollen joint count
SLE	Systemic Lupus Erythematosus
SPA	Spondyloarthritis
SS	Sjogren syndrome
SSc	Systemic sclerosis
SSZ	Sulphasalazine
STAT	Signal transducers and activators of transcription
TAC	Tacrolimus
TGF-β	Transforming growth factor-beta
Th	T-helper
TJC	Tender joint count
TLC	Total leukocytic count
TLR	Toll like receptor
TNF	Tumor necrosis factor
TNFAIP3	Tumour necrosis factor alpha-induced protein 3
TNF-α	Tumor necrosis factor-alpha
tsDMARDS	Targeted synthetic disease modifying anti-rheumatic drugs
TYK	Tyrosine kinase
VAS	Visual analogue scale

List of Tables

Table No.	Title	Page
Table (1):	Environmental and other factors associated with rheumatoid arthritis risk	6
Table (2):	The ACR/EULAR 2010 classification criteria for RA.....	17
Table (3):	Classification criteria for PsA (CASPAR)	55
Table (4):	Modification of GRAPPA grid proposed for CPDAI	60
Table (5):	Important capillaroscopic parameters.....	75
Table (6):	Scleroderma pattern.....	81
Table (7):	DAS28-ESR score Interpretation	85
Table (8):	Demographic data among our studied PsA patients (20) and RA patients (20).....	93
Table (9):	Articular manifestations among our studied PsA patients (20) and RA patients (20).....	94
Table (10):	Extra-articular manifestations among our studied PsA patients (20) and RA patients (20).....	95
Table (11):	Drug intake among our studied PsA patients (20) and RA patients (20).....	95

List of Tables

Table No.	Title	Page
Table (12):	DAS28 score among our studied PsA patients (20) and RA patients (20).....	96
Table (13):	Laboratory data among our studied PsA patients (20) and RA patients (20)	96
Table (14):	Nail fold capillaroscopy findings among our studied PsA patients (20) and RA patients (20).....	97
Table (15):	Comparison between our studied PsA patients (20) and RA patients (20) as regards demographic data	99
Table (16):	Comparison between our studied PsA patients (20) and RA patients (20) as regards articular manifestations	101
Table (17):	Comparison between our studied PsA patients (20) and RA patients (20) as regard drug intake	103
Table (18):	Comparison between our studied PsA patients (20) and RA patients (20) as regards DAS28 score.....	105
Table (19):	Comparison between our studied PsA patients (20) and RA patients (20) as regards laboratory data	107
Table (20):	Comparison between our studied PsA patients (20) and RA patients (20) as regards capillary microscopy findings.....	108

List of Tables

Table No.	Title	Page
Table (21):	Correlation between capillary microscopy findings and parameters of disease activity in our studied PsA patients (20)	114
Table (22):	Relation between capillary microscopy findings and parameters of disease activity in our studied PsA patients (20)	117
Table (23):	Relation between capillary microscopy findings (distribution) and parameters of disease activity in our studied PsA patients (20)	118
Table (24):	Relation between capillary microscopy findings (hemorrhage and Sub papillary plexus) and parameters of disease activity in our studied PsA patients (20) ...	119
Table (25):	Correlation between capillary microscopy findings and parameters of disease activity in our studied RA patients (20)	121
Table (26):	Relation between capillary microscopy findings (shape) and parameters of disease activity in our studied RA patients (20)	122
Table (27):	Relation between capillary microscopy findings (hemorrhage) and parameters of disease activity in our studied RA patients (20)	124

List of Figures

Figure No.	Title	Page
Fig. (1):	Immune pathways in rheumatoid arthritis MMP: matrix metalloproteinase....	10
Fig. (2):	A hand affected by rheumatoid arthritis	11
Fig. (3):	X-ray of the hand in rheumatoid arthritis	20
Fig. (4):	Algorithm of 2016 (EULAR) recommendations on rheumatoid arthritis (RA) management	38
Fig. (5):	Susceptibility genes for psoriasis, and by analogy for psoriatic arthritis.....	44
Fig. (6):	Functional model of enthesitis.....	48
Fig. (7):	Peripheral hand joint involvement along with psoriatic skin lesion and nail changes.....	50
Fig. (8):	A patient with arthritis mutilans with digital shortening.....	51
Fig. (9):	(A) Schematic of joint structure and (B) photograph of common symptoms in psoriatic arthritis.....	52
Fig. (10):	Nail psoriasis	53
Fig. (11):	Ankylosis of distal interphalangeal joint on both hands, pencil in cup deformity in the first left interphalangeal joint on radiography ...	57

List of Figures

Figure No.	Title	Page
Fig. (12):	The EULAR 2015 algorithm for treatment of PsA with pharmacological non-topical treatments.....	68
Fig. (13):	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis treatment schema for active psoriatic arthritis (PsA)	70
Fig. (14):	Different tools for nailfold capillaroscopic analysis	73
Fig. (15):	Normal capillaroscopic image with U-shaped capillaries	76
Fig. (16):	Capillaroscopic pattern in RA patient ..	78
Fig. (17):	Capillaroscopic pattern in PsA patient with involvement of small joints of the hands	79
Fig. (18):	Scleroderma pattern. Early (A), active (B) and late (C, D) patterns	81
Fig. (19):	Schematic drawing of the front portion of a nailfold capillary loop.....	88
Fig. (20):	Distribution of capillary per mm.....	90
Fig. (21):	Showing tortuous capillaries in PsA patient	98
Fig. (22):	Showing tortuous capillaries and hemorrhage in PsA patient	98
Fig. (23):	Showing hairpin capillaries in RA patient	98

List of Figures

Figure No.	Title	Page
Fig. (24):	Showing hairpin and organized capillaries in a RA patient	98
Fig. (25):	Comparison between our studied PsA patients (20) and RA patients (20) as regards age	100
Fig. (26):	Comparison between our studied PsA patients (20) and RA patients (20) as regards sex	100
Fig. (27):	Comparison between our studied PsA patients (20) and RA patients (20) as regards articular manifestations	102
Fig. (28):	Comparison between our studied PsA patients (20) and RA patients (20) as regards articular manifestations	102
Fig. (29):	Comparison between our studied PsA patients (20) and RA patients (20) as regard drug intake	104
Fig. (30):	Comparison between our studied PsA patients (20) and RA patients (20) as regards DAS28 score.....	106
Fig. (31):	Comparison between our studied PsA patients (20) and RA patients (20) as regards DAS28 score and assessment of activity	106
Fig. (32):	Showing tortuous, low density capillaries in a PsA patient	110

List of Figures

Figure No.	Title	Page
Fig. (33):	Showing disorganized, tortuous capillaries in a PsA patient	110
Fig. (34):	Showing hemorrhage, tortuous capillaries in a PsA patient	110
Fig. (35):	Showing hairpin, organized capillaries in a RA patient	110
Fig. (36):	Comparison between our studied PsA patients (20) and RA patients (20) as regards capillary microscopy findings.....	111
Fig. (37):	Comparison between our studied PsA patients (20) and RA patients (20) as regards capillary length.....	111
Fig. (38):	Comparison between our studied PsA patients (20) and RA patients (20) as regards capillary shape	112
Fig. (39):	Comparison between our studied PsA patients (20) and RA patients (20) as regards capillary distribution ...	112
Fig. (40):	Comparison between our studied PsA patients (20) and RA patients (20) as regards capillary microscopy findings as avascular areas, hemorrhage, subpapillary plexus	113
Fig. (41):	Correlation between capillary density and number of tender joints in our studied PsA patients (20).....	115

List of Figures

Figure No.	Title	Page
Fig. (42):	Correlation between capillary width and number tender joints in our studied PsA patients (20).....	115
Fig. (43):	Correlation between capillary arterial diameter and CRP in our studied PsA patients (20).....	116